Macrophage Pharma Extends Series A Round to Include New Investor Merck Ventures

Merck Ventures Joins Investment Syndicate and the Board of Macrophage Macrophage Pharma Limited (‘MPL’) the immuno-oncology research and development company focused on macrophage modulation in the tumour microenvironment (TME), announced today that it has raised additional funding from Merck Ventures to complete the Series A Financing announced in January 2017.  Merck Ventures joins the existing … Continue reading “Macrophage Pharma Extends Series A Round to Include New Investor Merck Ventures”

Macrophage Pharma Appoints Development Director

Dr Joanne Bedwell-Garner joins management team Macrophage Pharma Limited (‘MPL’) the immuno-oncology development company, announced today that it has appointed Dr Joanne Bedwell-Garner as Development Director. Dr Bedwell-Garner will be responsible for advancing the clinical development of Macrophage Pharma’s lead programme, MPL-5821. This announcement follows the recent £9 million Series A financing, which was led … Continue reading “Macrophage Pharma Appoints Development Director”

Macrophage Pharma Raises £9 Million in Series A Financing and Acquires Immune-oncology Technology Platform

Macrophage Pharma Limited, a newly formed immune-oncology company, today announced that it has successfully raised £9 million in a Series A equity financing round. The Company has also acquired global rights to a novel technology platform, Esterase Sensitive Motif (ESM), from Chroma Therapeutics Limited (Oxford, UK) together with discovery stage therapeutic assets. Macrophage Pharma was … Continue reading “Macrophage Pharma Raises £9 Million in Series A Financing and Acquires Immune-oncology Technology Platform”